Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.
about
Highly accurate two-gene classifier for differentiating gastrointestinal stromal tumors and leiomyosarcomasEfficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic reviewOsteosarcoma in Korean children and adolescentsManagement Strategies in Advanced Uterine Leiomyosarcoma: Focus on TrabectedinPazopanib in the treatment of soft tissue sarcomaEGFR inhibition abrogates leiomyosarcoma cell chemoresistance through inactivation of survival pathways and impairment of CSC potentialA Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology Group StudyFixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.The evolution of systemic therapy in sarcoma.Ifosfamide, carboplatin and etoposide (ICE) as second-line regimen alone and in combination with regional hyperthermia is active in chemo-pre-treated advanced soft tissue sarcoma of adults.Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.Trabectedin and its potential in the treatment of soft tissue sarcoma.Trabectedin for the management of soft-tissue sarcoma.Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II studyPhase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma.Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas.Efficacy and safety of gemcitabine-docetaxel combination therapy for recurrent or refractory high-grade osteosarcoma in China: a retrospective study of 18 patients.Combination of trabectedin and gemcitabine for advanced soft tissue sarcomas: results of a phase I dose escalating trial of the German Interdisciplinary Sarcoma Group (GISG).A systematic review of gemcitabine and taxanes combination therapy randomized trials for metastatic breast cancer.A Phase II Study of Gemcitabine, Vincristine, and Cisplatin As Second-Line Treatment for Patients with Advanced Soft Tissue Sarcoma.A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D.Docetaxel, bevacizumab, and gemcitabine for very high risk sarcomas in adolescents and young adults: A single-center experience.Outcomes of first-line chemotherapy in patients with advanced or metastatic leiomyosarcoma of uterine and non-uterine originEfficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysisRole of expert centres in the management of sarcomasClinical management of secondary angiosarcoma after breast conservation therapyRecombined humanized endostatin (Endostar) combined with chemotherapy for advanced bone and soft tissue sarcomas in stage IV.Locally-advanced unresected uterine leiomyosarcoma with triple-modality treatment combining radiotherapy, chemotherapy and hyperthermia: A case report.Pulmonary toxicity among cancer patients treated with a combination of docetaxel and gemcitabine: a meta-analysis of clinical trials.Role of trabectedin in the treatment of soft tissue sarcomaPrimary leiomyosarcoma of the seminal vesicle: case report and review of the literatureDiagnosis and treatment of sarcoma of the uterus. A review.Isolated cutaneous metastasis of uterine leiomyosarcoma: case report and review of literature.Leiomyosarcoma of the sigmoid colon with multiple liver metastases and gastric cancer: a case report.Inhibition of uterine sarcoma cell growth through suppression of endogenous tyrosine kinase B signaling.First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group studyIntegrative genomic characterization and a genomic staging system for gastrointestinal stromal tumors.Epidemiology and therapies for metastatic sarcomaEfficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case seriesRecent advances in understanding and managing leiomyosarcomas
P2860
Q24685605-0438E4C8-9FCC-4525-8BB8-F3D1CEC1EEBDQ26822530-17797287-D8C2-4465-9535-25C91DB769E8Q28083794-261A85A8-1FB4-45EE-B1B7-11C08E80AB73Q28087771-8F2CF39D-4678-4544-8002-443AE6B7FA20Q28269229-01B5E28D-67A3-42ED-9B8B-6EE211A419C1Q28484249-01F03612-6FC9-4385-BB0D-9C298A346755Q30370631-26F3789D-AF97-40AF-B014-7702C23F2C8DQ30439459-2F4BB747-C4E5-4EB8-8119-2E909606B834Q33274710-D9D08640-F95E-4984-A4E5-BD2246AA7806Q33362634-224F64F3-5622-4CA6-A38B-C0C31CB47D02Q33379886-8ED4798F-7D71-44CC-8566-AC34043AF3ADQ33380903-9B1DBB03-B41A-4EE2-B878-067AEF57C32BQ33384836-F59D231D-ADDC-4A8C-8E9F-C92991EF9F7CQ33386535-5F4CB862-F254-4F6E-B64F-2652FAC7F819Q33397403-90517C25-FB6D-4596-AF5B-342B25678C5DQ33399473-1607E4A9-8F0A-43B3-93AE-2072C404B9EDQ33400419-9E09542B-50DE-4E7B-AE71-CB4CD24CC51CQ33419792-29519A0B-DA7D-4E36-AAF9-63C6AE177F80Q33423308-4790F510-34DE-4794-A633-B0B21D9DE1DBQ33427160-775D831C-7744-4BFC-8CB3-1BD891595AE9Q33438485-F60BD25D-8936-4B73-87DA-B41E0446F711Q33439510-F25565A7-982A-41E6-8C24-A9A3F4CB8980Q33523297-C01E8968-2D6D-4148-9FBE-E37D95963E38Q33657779-8CFB085C-E779-4652-B50D-8EFDE8AC3086Q33697957-1060FBBA-895B-491E-ADA5-81D635626D1EQ33751719-DBD45487-193A-47EE-B91A-619EBF609E54Q33829625-1D99E704-A57D-4416-8389-923F5E4A6827Q33844215-A98B9CC6-41FF-4024-A158-038370B1EEB8Q33891037-8BF00711-F4D0-4A13-8B03-D2CC597F9982Q33916011-EA4ECDF3-963B-4602-9C65-1E5552E7D1A1Q33975569-D24FFEF3-101E-404E-9A24-7809B8F2EE44Q34336818-BC7F6561-F33F-4596-B67B-370958100A3BQ34343122-C699DA09-36D6-40DA-9588-E90AC1A6E13DQ34360332-7BF4E5CA-668C-48B9-BE85-6A97CADE3F62Q34387629-93C99BAD-CFFC-4890-BCA1-AA60DEE8B478Q34413659-ACCC2808-DACB-4B30-81F5-4AEAD581B4B7Q34432570-F8F2FA6B-19B6-4F00-A31E-0522AF8422AEQ34652142-96171390-C663-4344-88E9-A8479E6226DBQ34669352-74FA4D45-05A9-4DC7-9542-23B8DD416BDFQ34670825-161F7A89-D152-4B69-A555-B3998BACD191
P2860
Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Gemcitabine and docetaxel in p ...... : results of a phase II trial.
@ast
Gemcitabine and docetaxel in p ...... : results of a phase II trial.
@en
type
label
Gemcitabine and docetaxel in p ...... : results of a phase II trial.
@ast
Gemcitabine and docetaxel in p ...... : results of a phase II trial.
@en
prefLabel
Gemcitabine and docetaxel in p ...... : results of a phase II trial.
@ast
Gemcitabine and docetaxel in p ...... : results of a phase II trial.
@en
P2093
P356
P1476
Gemcitabine and docetaxel in p ...... a: results of a phase II trial
@en
P2093
Carol Aghajanian
David R Spriggs
E Venkatraman
Gennifer Geller
Martee L Hensley
Meghan Lovegren
Paul Sabbatini
Richard Barakat
William Tong
P304
P356
10.1200/JCO.2002.11.050
P407
P577
2002-06-01T00:00:00Z